Brief: Vaccinex Intends To Use Net Proceeds From Private Placement To Fund Ongoing Development Of Pepinemab
10/07/2020 11:48
July 10 (Reuters) - Vaccinex Inc VCNX.O :
* VACCINEX INC - ON JULY 9, ENTERED INTO A STOCK PURCHASE
AGREEMENT WITH FRIEDBERG GLOBAL-MACRO HEDGE FUND, LTD
* VACCINEX INC - INVESTOR AGREED TO PURCHASE FROM CO 1.1
MILLION
SHARES OF COMMON STOCK AT $3.55 PER SHARE
* VACCINEX INC - INTENDS TO USE NET PROCEEDS FROM PRIVATE
PLACEMENT TO FUND ONGOING DEVELOPMENT OF PEPINEMAB
Source: (https://bit.ly/2W7emCz)
Further company coverage: VCNX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vaccinex
See all newsBrief: Vaccinex Reports Third Quarter 2024 Financial Results And Provides Corporate Update
Brief: Vaccinex Says On Oct 7, Got Letter From The Nasdaq Listing Staff Stating That Co Had Not Regained Compliance With The Equity Standard
Brief: VaccinexExercise Of Warrants For $6.2 Million In Gross Proceeds
Brief: Vaccinex Provides Update On New Findings For Signal-Ad Phase 1B/2 Trial Of Pepinemab In Alzheimer’S Disease
Brief: Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease